Professor Linda Mileshkin is a medical oncologist and a clinical researcher with a particular interest in the treatment of gynaecological cancers, as well as the supportive care of people affected by cancer. She also runs Australia’s only specialist clinic dedicated to the care of people affected by Cancer of Unknown Primary (CUP). She is the Interim Director of Medical Oncology at the Peter MacCallum cancer Centre and the clinical trials lead for Gynae-Oncology in the Parkville Cancer Clinical Trials Unit. She is also very involved in the Australia New Zealand Gynaecological Oncology Group (ANZGOG) as a member of multiple committees and Chair of the EDEN initiative to improve outcomes for women with Endometrial cancer.

Associate Professor Orla McNally is a sub-specialist surgical Gynaecological Oncologist and the Director of Oncology and Dysplasia Unit at The Royal Women’s Hospital, Melbourne, Australia, as well as Gynaecological Tumour Stream Lead for the Victorian Comprehensive Cancer, Australia. Orla is a Clinical Associate Professor in the Department of Obstetrics and Gynaecology at the University of Melbourne. As well as being the lead for the Gynae-oncology multidisciplinary team at The Royal Women’s Hospital Orla provides clinical support to Peter McCallum Cancer Centre and Royal Melbourne Hospital. Originally from Ireland, Orla first trained in general surgery and was dismayed by the poor outcomes for women with ovarian cancer and so her career moved into gynaecological cancer. During her time working in the NHS, United Kingdom and in the last thirteen years in Melbourne, Orla has led and taught multidisciplinary care and in particular offering women the opportunity to be involved in research, in particular clinical trials, from prevention through to end of life at any time in their cancer journey or prevention. To this end Orla collaborates nationally through ASGO, ANZGOG and CTA, and internationally through IGCS, GCIG and ESGO.

Dr Michelle Vaughan works as a Consultant Medical Oncologist at Christchurch Hospital and St Georges Cancer Care Centre, New Zealand. She trained in Auckland and London, and also worked as the European Medical Director for a biotechnology company earlier in her career. She has a special interest in gynaecological malignancies and has enjoyed clinical research and teaching for over 20 years. Dr Vaughan has been an active member of ANZGOG since 2006, on the RAC, and the Cervical and Endometrial Tumour Working Groups.

Dr David Chang obtained MBBS (with Honours) at the University of Western Australia in 2008. He completed radiation oncology training at the Peter MacCallum Cancer Centre, Melbourne in 2015 and obtained a Fellowship of the Royal Australian and New Zealand College of Radiologists in 2016. In 2012, he won the CE Eddy Prize for being the most successful candidate in the Phase 1 Radiation Oncology Examinations and in 2016 won the FRO Bourne Langlands Prize for exceptional research. David completed his PhD studies whilst working as a clinical fellow at the Prince of Wales Hospital, Sydney. In 2019, he won the David Wigg Prize for Radiobiology Research for this work. In 2019 and 2020, he was employed as a radiation oncologist and director of training at the Olivia Newton-John Cancer Centre, Melbourne. David returned to the Peter MacCallum Cancer Centre, Melbourne in 2020 and is currently a full-time clinical radiation oncologist with an interest in Gynae and GU oncology. He is a member of the Royal Australian and New Zealand College of Radiologists (RANZCR), Trans-Tasman Radiation Oncology Group (TROG), Australia New Zealand Gynaecological Oncology Group (ANZGOG, ASM Program Steering Committee 2022 and 2023), Gynaecological Oncology Radiation Oncology Collaboration (GOROC), Australia and New Zealand Urogenital and Prostate Cancer Trials Groups (ANZUP) and Australian Brachytherapy Group (ABG, committee member).

Dr Diana Adams is a practising Senior Staff Specialist Medical Oncologist at the Macarthur Cancer Therapy Centre. She is a passionate advocate for enhancing the support to those with a diagnosis or cancer and to their carers. She has spoken at National Oncology meetings with ANZGOG to enhance the awareness of obesity driven cancers, NSW Cancer Council webinars to promote exercise in cancer care and COSA meetings on Survivorship Care Plans. She represents Clinical Oncology on the Executive Committee of the Clinical Oncology Society of Australia (COSA) Exercise and Cancer Group promoting Exercise in Cancer Care. Dr Diana Adams is the past Chair of the ANZGOG Uterine Tumour Working Group.

Dr Deborah Smith is a Senior Anatomical Pathologist at Mater Pathology in Brisbane, Queensland Australia and Honorary Fellow, University of Queensland and Mater Research. Dr Smith has a longstanding interest in gynae oncology pathology and undertook a Fellowship in Gynaecologic Pathology at the University Hospital Network, Toronto, Canada in 2009. Mater Pathology where she currently works serves both private and public gynaecology and gynae oncology clinical teams.

Dr Smith has a strong commitment to teaching, including medical students, registrars and clinicians from other specialties. She is also actively involved in gynaecologic oncological research, with a special interest in endometrioid neoplasia. Dr Smith is a member of the International Society for Gynaecological Pathologists (ISGyP) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG).

Associate Professor Pam Pollock completed her PhD at QIMR in 2000 and a NHMRC postdoctoral fellowship at the NIH in 2003, both focussed on the genetics of sporadic and familial melanoma. In 2003 she was recruited to the Translational Genomics Institute (TGen) in Phoenix, Arizona to head a research laboratory. She was the first to report FGFR2 mutations in endometrial cancer in 2007 and has since built an international reputation in this field. She returned to Brisbane in 2010 and heads the Endometrial Cancer laboratory within QUT’s School of Biomedical Science. She was involved in the original TCGA study reporting multiple molecular subtypes of endometrial cancer and is also a member of the transPORTEC consortium with multiple publications on risk stratification in endometrial cancer using different molecular markers. Within ANZGOG Dr Pollock provides preclinical and translational scientific expertise to the research advisory committee, the Uterine Tissue Type Working Group, the Basic and Translational Research Group associated with the EDEN initiative and is also a member of TR-ANZGOG. At QUT, she is Chair of the University Biosafety committee and the Course coordinator for QUT’s Bachelor of Biomedical Science Honours program. Outside of work, she is a Mum to three teenagers and a beautiful Burmese cat called Opal while being barely tolerated by the second cat in the house. She is very lucky to have a scientist husband having just published her second paper with him in 2022 after they met working together on their first paper published in 1996.

Associate Professor Susan Jordan is a medically trained cancer epidemiologist who is currently Associate Professor of Epidemiology at the School of Public Health, The University of Queensland. Before moving into research, she worked in rural and urban general practice for over 10 years and brings that clinical experience to her research. Susan leads a program of research which aims to increase knowledge of cancer causes and to investigate variations in patient diagnosis, care, and outcomes. Her current research interests include the aetiology, diagnosis and care pathways for ovarian, and endometrial and thyroid cancers; she has a particular interest in how reproductive factors and chronic health conditions influence the development of these cancers. She has over 130 publications, mostly in the field of gynaecological cancer, and > AUD 10 million in grant funding. Her research employs a broad range of methods including individual patient and clinician surveys, molecular epidemiology, pooling of consortia data, and large-scale linkage of administrative data.

Dr Goodwin is a senior staff specialist working at Concord Repatriation General Hospital as a medical oncologist specializing in breast cancer and as a Cancer Geneticist. She was awarded a NSW Cancer Institute Fellowship to train in Cancer Genetics in 2006 and then awarded a second fellowship again in 2007. She commenced working as the head of the Cancer Genetics Service encompassing Royal Prince Alfred and Concord Hospitals in 2011.

She is committed to improving the care of women with heritable causes for breast cancer by supporting clinical trials of personalized therapy for women with heritable predispositions to breast cancer, encompassing breast cancer prevention trial BRCA-P, adjuvant therapy trials (Olympia) and treatment for metastatic breast cancer (EMBRACA). She is interested in cancer risk management approaches for people with hereditary cancer syndrome and is part of the National Inherited Cancer Connect (ICCon) research team and has been a member of. To support evidence-based practice she has been part of the eviQ Cancer Genetics Reference Committee since it was first established to develop guidelines for offering cancer genetic testing and cancer risk management protocols for people with hereditary cancer syndromes.

Dr Goodwin is committed to use of high quality evidence- based research, and holds the position of Joint Co-coordinating editor of the Cochrane Breast Cancer Group which is part of the NHMRC Clinical Trials Centre, University of Sydney.

Ms Nicole Kinnane is a project manager (Australian Cancer Survivorship Centre), currently undertaking a competitively awarded 12 month secondment to The Academic Nursing Unit at Peter MacCallum Cancer Centre.   Nicole is also nationally recognised, specialist gynae-oncology nurse with expertise in cancer survivorship working as a nurse consultant in the gynae-oncology service at Peter MacCallum Cancer Centre. Nicole completed her Master of Philosophy at Melbourne University 2022 with first class honours. The thesis examined the patterns of follow up and disease outcomes for women treated for endometrial cancer over a 10-year period and explored experiences of follow up via interviews. The data showed the current model of follow-up is burdensome for patients and fails to comprehensively address survivorship issues that matter most to women. Nicole’s portfolio for the Australian Cancer Survivorship Centre includes health care professional and consumer education, implementation of survivorship initiatives in the clinical setting, and development of health professional and consumer survivorship resources and tools Nicole is committed to improving the outcomes for patients diagnosed with cancer and their families during and after treatment. Her dual roles allow her to implement survivor care recommendations in the clinical setting. Her career objective is to improve outcomes and experiences of cancer survivors through a dedicated nurse clinician-researcher role.

Kathy is a Registered Nurse working as the clinical trials coordinator for the bowel cancer research team, located at Flinders Centre for Innovation in Cancer, South Australia.

At the age of 46, Kathy was diagnosed with Ovarian and Endometrial Cancer. It was after her diagnosis and treatment that she discovered a strong family history in gynaecological and colorectal cancers. When more family members were diagnosed with cancer, genetic testing was initiated and Lynch Syndrome was confirmed. Since then, Kathy has become an advocate for change to support those with Lynch Syndrome and educate health professionals by working closely with Lynch Syndrome Australia, by creating videos and organising educational events.

Kathy is also on the consumer representative panel (CRP) for the Australia New Zealand Gynaecological Oncology Group (ANZGOG) who focus on improving outcomes for women with gynaecological cancers through collaboration and research.